CV Outcomes in Diabetes

Risk reduction with antihyperglycaemic therapies


Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D).


The opportunity for CV disease prevention in patients with T2D has recently expanded with antihyperglycaemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE). Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.


CV specialists are well-positioned to play a key role in managing patients with T2D, including screening, aggressively treating CV risk factors, and incorporating the use of antihyperglycaemic agents into routine practice.

Close X
Other videos you might like

Section Advisor

Professor Mikhail N Kosiborod

Saint Luke's America Heart Institute, Kansas City, MO, US

The Radcliffe diabetes and CVD risk program is supported by an educational grant from Novo Nordisk.

Recent Videos

Video Series

e-SPACE Cardio-Renal-Metabolic 2023

Fausto J Pinto, Kerri L Cavanaugh, John Spertus, et al

Watch time: 16h 19m 46s (19 videos)


ACC 23 Late-breaking Discussion: The COORDINATE-Diabetes Trial

Harriette Van Spall, Neha Pagidipati, Christopher B Granger, et al

Watch time: 17m 32s


CRT 23: PCI Vs CABG in Left Main CAD With or Without Diabetes

Prakriti Gaba,

Watch time: 4m 19s

Video Series

The Changing Face of Lipid Management in the UK

Ahmet Fuat, Jim Moore, Gary Ford, et al

Watch time: 1h 35m (4 videos)

Video Series

CVD and Type 2 Diabetes

Tina Vilsbøll, Neha Pagidipati, John Buse, et al

Watch time: 2h 2m 59s (19 videos)